Incannex Healthcare IXHL 深 沪
等待开盘 07-02 09:30:00 美东时间
3.71
-0.050
-1.33%
华盛通- 最 高3.915
- 今 开3.74
- 成交量 18.04万股
- 最 低 3.64
- 昨 收 3.76
- 总市值 4438.85万
- 52周最高 49.80
- 市盈率 静 --
- 换手率 1.51%
- 52周最低 2.49
- 委 比 36.71%
- 总股本 1196.46万
- 历史最高 10800.00
- 量 比 0.60
- 振 幅 7.31%
- 历史最低 2.40
- 每 手 1
- 风险率 6.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Incannex Healthcare Secures U.S. Patent For Compositions And Methods Of Treatment For Obstructive Sleep Apnea
The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA). The patent is expected to have a baseline expiry date of 9 July 2040 and the Company is exploring its eligibility for patent t...
06-25 20:05
Incannex Secures Key U.S. Patent for IHL-42X
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
06-25 19:57
Incannex wins US patent for IHL-42X obstructive sleep apnea therapy
Incannex wins US patent for IHL-42X obstructive sleep apnea therapy Incannex won a U.S. patent covering the IHL-42X composition and methods to treat obstructive sleep apnea. Baseline patent expiry set for July 9, 2040; patent term extension under review pending potential FDA approval. Move strengthe
06-25 19:31
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Inc. announced the USPTO has granted a key patent for its IHL-42X composition and therapeutic methods to treat Obstructive Sleep Apnea (OSA). The patent, set to expire in 2040, strengthens the company's intellectual property and supports long-term market exclusivity. IHL-42X, a novel oral therapy, addresses significant unmet needs in OSA treatment, with poor patient adherence to current options. The patent, combined with FDA F...
06-25 12:00
Incannex Healthcare Secures Major Non-Dilutive R&D Funding
The latest update is out from Incannex Healthcare Limited Sponsored ADR ( ($IXH...
06-10 20:01
美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Alliance Global Partners Initiates Coverage On Incannex Healthcare with Buy Rating, Announces Price Target of $18
Alliance Global Partners analyst James Molloy initiates coverage on Incannex Healthcare (NASDAQ:IXHL) with a Buy rating and announces Price Target of $18.
06-08 22:05
Incannex Healthcare Q3 EPS $(0.35) Beats $(0.79) Estimate
Incannex Healthcare (NASDAQ:IXHL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.79) by 55.7 percent. This is a 94.35 percent increase over losses of $(6.19) per share
05-16 07:07
Incannex Q3 FY26 operating loss narrows 19% to USD 4.05 million
Incannex Q3 FY26 operating loss narrows 19% to USD 4.05 million Incannex Healthcare posted a comprehensive loss of USD 4.35 million for quarter ended March 31, 2026, widening 7% from USD 4.06 million a year earlier. Operating loss narrowed 19% to USD 4.05 million as research and development costs fe
05-15 21:30
Incannex Wins MedTech Award for IHL-42X Sleep Therapy
Incannex Healthcare Limited Sponsored ADR ( ($IXHL) ) has shared an announcemen...
05-12 20:42
